Role of the active vitamin D metabolite and 1 alpha-hydroxylated analogs in the treatment of postmenopausal osteoporosis. 1992

A Caniggia, and F Loré, and R Nuti, and G Martini, and B Frediani, and G Di Cairano
Mineral Metabolic Unit, University of Siena, Italy.

UI MeSH Term Description Entries
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D002117 Calcitriol The physiologically active form of vitamin D. It is formed primarily in the kidney by enzymatic hydroxylation of 25-hydroxycholecalciferol (CALCIFEDIOL). Its production is stimulated by low blood calcium levels and parathyroid hormone. Calcitriol increases intestinal absorption of calcium and phosphorus, and in concert with parathyroid hormone increases bone resorption. 1 alpha,25-Dihydroxycholecalciferol,1 alpha,25-Dihydroxyvitamin D3,1, 25-(OH)2D3,1,25(OH)2D3,1,25-Dihydroxycholecalciferol,1,25-Dihydroxyvitamin D3,1 alpha, 25-dihydroxy-20-epi-Vitamin D3,1,25(OH)2-20epi-D3,1,25-dihydroxy-20-epi-Vitamin D3,20-epi-1alpha,25-dihydroxycholecaliferol,Bocatriol,Calcijex,Calcitriol KyraMed,Calcitriol-Nefro,Decostriol,MC-1288,MC1288,Osteotriol,Renatriol,Rocaltrol,Silkis,Sitriol,Soltriol,Tirocal,1 alpha,25 Dihydroxyvitamin D3,1,25 Dihydroxycholecalciferol,1,25 Dihydroxyvitamin D3,1,25 dihydroxy 20 epi Vitamin D3,Calcitriol Nefro,D3, 1 alpha,25-Dihydroxyvitamin,D3, 1,25-Dihydroxyvitamin,D3, 1,25-dihydroxy-20-epi-Vitamin,KyraMed, Calcitriol,MC 1288
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D006887 Hydroxycholecalciferols Hydroxy analogs of vitamin D 3; (CHOLECALCIFEROL); including CALCIFEDIOL; CALCITRIOL; and 24,25-DIHYDROXYVITAMIN D 3. Hydroxyvitamins D,Hydroxycholecalciferol
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D015663 Osteoporosis, Postmenopausal Metabolic disorder associated with fractures of the femoral neck, vertebrae, and distal forearm. It occurs commonly in women within 15-20 years after menopause, and is caused by factors associated with menopause including estrogen deficiency. Bone Loss, Perimenopausal,Bone Loss, Postmenopausal,Perimenopausal Bone Loss,Postmenopausal Bone Loss,Postmenopausal Osteoporosis,Osteoporosis, Post-Menopausal,Bone Losses, Perimenopausal,Bone Losses, Postmenopausal,Osteoporoses, Post-Menopausal,Osteoporoses, Postmenopausal,Osteoporosis, Post Menopausal,Perimenopausal Bone Losses,Post-Menopausal Osteoporoses,Post-Menopausal Osteoporosis,Postmenopausal Bone Losses,Postmenopausal Osteoporoses

Related Publications

A Caniggia, and F Loré, and R Nuti, and G Martini, and B Frediani, and G Di Cairano
February 2003, Journal of cellular biochemistry,
A Caniggia, and F Loré, and R Nuti, and G Martini, and B Frediani, and G Di Cairano
January 1981, Calcified tissue international,
A Caniggia, and F Loré, and R Nuti, and G Martini, and B Frediani, and G Di Cairano
January 1991, Steroids,
A Caniggia, and F Loré, and R Nuti, and G Martini, and B Frediani, and G Di Cairano
April 1985, Endocrinologia japonica,
A Caniggia, and F Loré, and R Nuti, and G Martini, and B Frediani, and G Di Cairano
January 2002, Journal of bone and mineral metabolism,
A Caniggia, and F Loré, and R Nuti, and G Martini, and B Frediani, and G Di Cairano
June 1998, Nihon rinsho. Japanese journal of clinical medicine,
A Caniggia, and F Loré, and R Nuti, and G Martini, and B Frediani, and G Di Cairano
May 1984, The British journal of surgery,
A Caniggia, and F Loré, and R Nuti, and G Martini, and B Frediani, and G Di Cairano
January 1984, Acta clinica Belgica,
A Caniggia, and F Loré, and R Nuti, and G Martini, and B Frediani, and G Di Cairano
August 1994, Rheumatic diseases clinics of North America,
A Caniggia, and F Loré, and R Nuti, and G Martini, and B Frediani, and G Di Cairano
January 2006, Current drug safety,
Copied contents to your clipboard!